Gold prices slip lower; consolidating after recent gains
McKesson Corporation (NYSE:MCK)’s stock has reached an unprecedented peak, marking an all-time high at $672, with InvestingPro data showing impressive returns of nearly 37% over the past six months. According to InvestingPro’s comprehensive analysis, the company maintains a "GREAT" overall financial health score of 3.07 out of 5. This milestone underscores the company’s robust performance in the market, reflecting a significant 24% increase in value over the past year. Investors have shown increased confidence in McKesson’s business model and growth prospects, propelling the stock to new heights and outperforming many of its peers in the healthcare sector. The impressive one-year change in the stock’s value highlights the company’s resilience and adaptability in a dynamic industry landscape. With a market capitalization of $83 billion and a consistent 32-year track record of dividend payments, McKesson demonstrates strong fundamentals. Based on InvestingPro’s Fair Value analysis, the stock appears slightly undervalued at current levels. Discover 15 additional exclusive insights about McKesson with a subscription to InvestingPro.
In other recent news, McKesson Corporation reported third-quarter earnings and revenue that did not meet analyst expectations, with adjusted earnings per share of $8.03 falling short of the anticipated $8.27. Despite this, McKesson raised its full-year earnings guidance, now expecting an adjusted EPS range of $32.55 to $32.95, slightly above the analyst consensus midpoint. Revenue for the quarter increased by 18% year-over-year to $95.29 billion, although it was below the forecasted $95.77 billion. In the U.S. Pharmaceutical (TADAWUL:2070) segment, revenue rose 19% to $87.1 billion, driven by increased prescription volumes and growth in the oncology platform. The company also announced plans to acquire a controlling interest in PRISM Vision Holdings LLC and Florida Cancer Specialists & Research Institute, aligning with its strategy to expand higher-margin specialty services. S&P Global Ratings revised McKesson’s outlook to positive from stable, affirming its ’BBB+’ rating, due to expected growth in its U.S. pharmaceutical segment and prescription technology business. Citi analyst Daniel Grosslight raised McKesson’s stock price target to $685, maintaining a Buy rating, following a mixed financial quarter where the pharmaceutical segment outperformed expectations. Additionally, McKesson has returned $3.1 billion to shareholders through share repurchases and dividends in the first nine months of the fiscal year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.